Your Health, We Care
Abrotinib, as a selective inhibitor of Janus kinase 1 (JAK1), has been widely studied for the treatment of moderate to severe atopic dermatitis.
Abrocetinib was compared head to head with dabigatran in a phase III clinical study, and the results showed that in multiple efficacy measures, Abrocetinib was statistically superior.
Focusing on the multi-version characteristics of this drug, patients and medical practitioners need to establish a clearer cognitive framework.How many versions of abuxitinib are t···【more】
Article source：Lucius LaosRelease date：2025-05-14Recommended：91
Focusing on the multi-version characteristics of this drug, patients and medical practitioners need to establish a clearer cognitive framework.How many versions of abuxitinib are t···【more】
Article source：Lucius LaosRelease date：2025-05-13Recommended：116
An innovative drug has attracted widespread attention in the medical field in recent years.What is Abuxitinib?The drug regulates abnormal responses of the immune system by selectiv···【more】
Article source：Lucius LaosRelease date：2025-05-13Recommended：127
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
